ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

Priya Rastogi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.